Complementary medicine for psychiatric disorders in children and adolescents

Current Opinion in Psychiatry

Volumn 21, Issue 4, 2008, Pages 350-355

  Soh, Nerissa L ^a   Walter, Garry ^b  

^a Northern Sydney Local Health Network   (Australia)

^b NONE

Author keywords

Attention deficit hyperactivity disorder; Bipolar disorder; Depression; Omega 3 fatty acids; St John's wort

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CARBAMAZEPINE; DOCOSAHEXAENOIC ACID; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; HYPERICUM REVOLUTUM EXTRACT; ICOSAPENTAENOIC ACID; IMIPRAMINE; KAVA EXTRACT; LINOLENIC ACID; LINSEED OIL; MELISSA OFFICINALIS EXTRACT; OMEGA 3 FATTY ACID; PAROXETINE; PHENYTOIN; PLACEBO; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; THEOPHYLLINE; VALERIAN;

ALTERNATIVE MEDICINE; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; AUTISM; BIPOLAR DISORDER; CHILD PSYCHIATRY; CLINICAL TRIAL; DECREASED APPETITE; DEPRESSION; DIET THERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HERBAL MEDICINE; HUMAN; LIVER TOXICITY; MAJOR DEPRESSION; MENTAL DISEASE; NONHUMAN; REVIEW; SCHIZOPHRENIA; SKIN DISEASE; SLEEP DISORDER; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; CHILD; COMPLEMENTARY THERAPIES; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; HUMANS; HYPERICUM; MENTAL DISORDERS; PHYTOTHERAPY; PLANT PREPARATIONS;

EID: 44649093335     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/YCO.0b013e328303672f     Document Type: Review

References (59)

1. Roy-Byrne PP, Bystritsky A, Russo J, et al. Use of herbal medicine in primary care patients with mood and anxiety disorders. Psychosomatics 2005; 46:117-122.
2. Jean D, Cyr C. Use of complementary and alternative medicine in a general pediatric clinic. Pediatrics 2007; 120:e138-e141.
3. Wilson KM, Klein JD, Sessleberg TS, et al. Use of complementary medicine and dietary supplements among U.S. adolescents. J Adolesc Health 2006; 38:385-394.
4. Hughes SC, Wingard DL. Children's visits to providers of complementary and alternative medicine in San Diego. Ambul Pediatr 2006; 6:293-296.
5. Sawni A, Ragothaman R, Thomas RL, et al. The use of complementary/ alternative therapies among children attending an urban pediatric emergency department. Clin Pediatr (Phila) 2007; 46:36-41.
6. Crawford NW, Cincotta DR, Lim A, et al. A cross-sectional survey of complementary and alternative medicine use by children and adolescents attending the University Hospital of Wales. BMC Complement Altern Med 2006; 6:16.
7. Smith C, Eckert K. Prevalence of complementary and alternative medicine and use among children in South Australia. J Paediatr Child Health 2006; 42:538-543.
8. Wilson K, Dowson C, Mangin D. Prevalence of complementary and alternative medicine use in Christchurch, New Zealand: children attending general practice versus paediatric outpatients. NZ Med J 2007; 120:U2464.
9. Wong HHL, Smith RG. Patterns of complementary and alternative medical therapy use in children diagnosed with autism spectrum disorders. J Autism Dev Disord 2006; 36:901-909.
10. Brown J, Cooper E, Frankton L, et al. Complementary and alternative therapies: Survey of knowledge and attitudes of health professionals at a tertiary pediatric/women's care facility. Complement Ther Clin Pract 2007; 13:194-200.
11. Clayton EH, Hanstock TL, Garg ML, et al. Long chain omega-3 polyunsaturated fatty acids in the treatment of psychiatric illnesses in children and adolescents. Acta Neuropsychiatrica 2007; 19:92-103. A well written review of omega-3 fats and their potential roles in treating bipolar disorder, depression, ADHD, autism, psychosis and schizophrenia in children and adolescents. The authors also highlight the safety profile and compare commercial popularity with the available evidence for efficacy.
12. Wozniak J, Biederman J, Mick E, et al. Omega-3 fatty acid monotherapy for pediatric bipolar disorder: a prospective open-label trial. Eur Neuropsychopharmacol 2007; 17:440-447. Although an open label trial, this is the only recent trial of omega-3 fatty acids as a treatment for childhood bipolar disorder.
13. Ohara K. The n-3 polyunsaturated fatty acid/dopamine hypothesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:469-474. An interesting and useful discussion on the mechanism of action of omega-3 fats in schizophrenia.
14. Joy CB, Mumby-Croft R, Joy LA. Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst Rev 2006; 3:CD001257.
15. Lin PY, Su KP. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry 2007; 68:1056-1061. A more recent meta-analysis than the Cochrane review (2006), but does not mention searching for unpublished trials. Also, it specifically excluded trials in children (i.e. Nemets et al. [21]).
16. Frais AT. Depression and the causal role of specific memory system degenerations: link may be supported by reported therapeutic benefits of omega 3 fatty acids. Med Hypotheses 2007; 69:67-69.
17. Antalis CJ, Stevens LJ, Campbell M, et al. Omega-3 fatty acid status in attention-deficit/hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids 2006; 75:299-308.
18. Mamalakis G, Kiriakakis M, Tsibinos G, et al. Depression and serum adiponectin and adipose omega-3 and omega-6 fatty acids in adolescents. Pharmacol Biochem Behav 2006; 85:474-479.
19. Richardson AJ. Omega-3 fatty acids in ADHD and related neurodevelopmental disorders. Int Rev Psychiatry 2006; 18:155-172.
20. Gracious B, Chirieac MC, Youngstrom EA. An RCT of flax oil in children and adolescents with bipolar disorder. NCDEU 46th Annual Meeting 2006; 222.
21. Nemets H, Nemets B, Apter A, et al. Omega-3 treatment of childhood depression: A controlled, double-blind pilot study. Am J Psychiatry 2006; 163:1098-1100.
22. Germano M, Meleleo D, Montorfano G, et al. Plasma, red blood cells phospholipids and clinical evaluation after long chain omega-3 supplementation in children with attention deficit hyperactivity disorder (ADHD). Nutr Neurosci 2007; 10:1-9.
23. Caniato RN, Alvarenga ME, Garcia-Alcaraz MA. Effect of omega-3 fatty acids on the lipid profile of patients taking clozapine. Aust NZ J Psychiatry 2006; 40:691-697.
24. Nicholson T. Complementary and alternative medicines (including traditional Maori treatments) used by presenters to an emergency department in New Zealand: a survey of prevalence and toxicity. NZ Med J 2006; 119:U1954.
25. Linde K, Mulrow CD, Berner M, et al. St John's Wort for depression (Review). Cochrane Database Syst Rev 2005; (2):CD000448.
26. Anghelescu IG, Kohnen R, Szegedi A, et al. Comparison of Hypericum extract WS5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study. Pharmacopsychiatry 2006; 39:213-219.
27. Hübner WD, Kirste T. Experience with St John's Wort (Hypericum perforatum) in children under 12 years with symptoms of depression and psychovegetative disturbances. Phytother Res 2001; 15:367-370.
28. Findling RL, McNamara NK, O'Riordan MA, et al. An open-label pilot study of St. John's wort in juvenile depression. J Am Acad Child Adolesc Psychiatry 2003; 42:908-914.
29. Simeon J, Nixon MK, Milin R, et al. Open-label pilot study of St. John's wort in adolescent depression. J Child Adolesc Psychopharmacol 2005; 15:293-301.
30. Rey JM, Walter G, Soh N. Complementary and alternative medicine (CAM) treatments and pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 2008; 47:364-368. A concise recent overview highlighting some of the clinical issues surrounding CAM use in children and adolescents.
31. Karalapillai DC, Bellomo R. Convulsions associated with an overdose of St John's wort (letter). Med J Aust 2007; 186:213-214.
32. Lilienfied SO. Scientifically unsupported and supported interventions for childhood psychopathology: A summary. Pediatrics 2005; 15:761-764.
33. Christison GW, Ivany K. Elimination diets in autism spectrum disorders: Any wheat amidst the chaff? J Dev Behav Pediatr 2006; 27:S162-S171.
34. Levy SE, Hyman SL. Novel treatments for autistic spectrum disorders. Ment Retard Dev Disabil Res Rev 2005; 11:131-142.
35. Jorm AF, Allen NB, O'Donnell CP, et al. Effectiveness of complementary and self-help treatments for depression in children and adolescents. Med J Aust 2006; 185:368-372.
36. •] and 2004 [39] commentaries.
37. Schab DW, Trinh NH. Do artificial food colors promote hyperactivity in children with hyperactive syndromes? A meta-analysis of double-blind placebo-controlled trials. J Dev Behav Pediatr 2004; 25:423-434.
38. Bateman B, Warner JO, Hutchinson E, et al. The effects of a double blind, placebo controlled, artificial food colourings and benzoate preservative challenge on hyperactivity in a general population sample of preschool children. Arch Dis Child 2004; 89:506-511.
39. Eigenmann PA, Haenggeli CA. Food colourings and preservatives: allergy and hyperactivity. Lancet 2004; 364:823-824.
40. ••] study draws attention to the clinical implications of food additives in relation to hyperactivity.
41. Lau K, McLean WG, Williams DP, et al. Synergistic interactions between commonly used food additives in a developmental neurotoxicity test. Toxicol Sci 2006; 90:178-187.
42. Kennedy DO, Scholey AB. The psychopharmacology of European herbs with cognition-enhancing properties. Curr Pharm Des 2006; 12:4613-4623.
43. Pittler MH, Ernst E. Kava extract versus placebo for treating anxiety (Review). Cochrane Database Syst Rev 2003; (1):CD003383.
44. Lim ST, Dragull K, Tang CS, et al. Effects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 rats. Toxicol Sci 2007; 97:214-221.
45. Jiang TF, Wang YH, Lv ZH, et al. Determination of kava lactones and flavonoid glycoside in Scorzonera austriaca by capillary zone electrophoresis. J Pharm Biomed Anal 2007; 43:854-858.
46. Jhoo JW, Freeman JP, Heinze TM, et al. In vitro cytotoxicity of nonpolar constituents from different parts of kava plant (Piper methysticum). J Agric Food Chem 2006; 54:3157-3162.
47. Connor KM, Payne V, Davidson JR. Kava in generalized anxiety disorder: three placebo-controlled trials. Int Clin Psychopharmacol 2006; 21:249-253.
48. Gastpar M, Klimm HD. Treatment of anxiety, tension and restlessness states with Kava special extract WS 1490 in general practice: a randomized placebo-controlled double-blind multicenter trial. Phytomedicine 2003; 10:631-639.
49. Centers for Disease Control and Prevention. Hepatic toxicity possibly associated with kava-containing products: United States, Germany and Switzerland 1999-2002. MMWR Morb Mortal Wkly Rep 2002; 51:1065-1067.
50. Kennedy DO, Little W, Haskell CF, et al. Anxiolytic effects of a combination of Melissa officinalis and Valeriana officinalis during laboratory induced stress. Phytother Res 2006; 20:96-102.
51. Müller SF, Klement S. A combination of valerian and lemon balm is effective in the treatment of restlessness and dyssomnia in children. Phytomedicine 2006; 13:383-387.
52. Lovera J, Bagert B, Smoot K, et al. Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial. Mult Scler 2007; 13:376-385.
53. Burns NR, Bryan J, Nettelbeck T. Ginkgo biloba: no robust effect on cognitive abilities or mood in healthy young or older adults. Hum Psychopharmacol 2006; 21:27-37.
54. Donfrancesco R, Ferrante L. Gingko biloba in dyslexia: A pilot study. Phytomedicine 2007; 14:367-370. There are so few trials of complementary medicines in children and this is one of the few - and the only one for gingko biloba, albeit an open-label trial.
55. Sakakibara H, Ishida K, Grundmann O, et al. Antidepressant effect of extracts from Ginkgo biloba leaves in behavioral models. Biol Pharm Bull 2006; 29:1767-1770.
56. Gardiner P, Kemper KJ. Herbs in pediatric and adolescent medicine. Pediatr Rev 2000; 21:44-57.
57. Lin YY, Chu SJ, Tsai SH. Association between priapism and concurrent use of risperidone and Ginkgo biloba. Mayo Clin Proc 2007; 82:1289-1290.
58. Einat H. Chronic oral administration of ginseng extract results in behavioral change but has no effects in mice models of affective and anxiety disorders. Phytother Res 2007; 21:62-66.
59. MacLennan AH, Myers SP, Taylor AW. The continuing use of complementary and alternative medicine in South Australia: costs and beliefs in 2004. Med J Aust 2006; 184:27-31.